Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Neoplasms

In brief

The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.

Key facts

Study ID

NCT00511849

Run by

Pfizer

People needed

43

Starts

2005-11-01

Expected to finish

2009-02-01

Last updated by the study team

2010-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically proven diagnosis of any advanced solid malignancy that is not amenable to treatment with curative intent
• Candidates for treatment with carboplatin and paclitaxel with maximum of 2 prior chemotherapy regimens
• ECOG performance status 0 or 1

You may not qualify if…

• Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to non-target, metastatic lesions
• Diagnosis of any second malignancy within the past 3 years

Where it is running

• Pfizer Investigational Site — Detroit, Michigan, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.